drug · antibody
tezepelumab
Marketedupdated 6mo agoby $AMGN AMGEN INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 6 investigational indications.
indications
investigational
Asthma
targets
Thymic stromal lymphopoietin
all catalysts(4)
approval · 4
Dec 17, 2021
approval
$AZN178.84-1.88%
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Feb 1, 2023
approval
$AZN178.84-1.88%
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
May 26, 2023
approval
$AZN178.84-1.88%
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Oct 17, 2025
approval
$AZN178.84-1.88%
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Trials studying tezepelumab
- phase3A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- phase3Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
- phase3Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
- phase3A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
- phase3Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
- —Tezspire Cardiac Events PASS
- —Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy
- phase3A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
News(10)
- Aclaris drops TSLP program from pipeline after flunking phase 2 eczema testA phase 2 study of Aclaris Therapeutics’ bosakitug in atopic dermatitis has missed its primary endpoint, adding to the setbacks anti-TSLP antibodies have encountered in the indication.fiercebiotech · 2d ago
- Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’Windward Bio’s IPO has blown to exactly the spot the Swiss biotech had been aiming for, bringing in $225 million to fund a pair of respiratory drugs licensed from China.fiercebiotech · 5d ago
- Windward prices $175M IPO to advance China-licensed lung drugsThe Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.biopharma_dive · 5d ago
- Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from ChinaWindward Bio is sailing toward the public markets with the aim of raising over $200 million in proceeds to fund two respiratory drugs licensed from China.fiercebiotech · 9d ago
- Alcon and OpenAI make acquisitions; Tezspire's latest Phase 3 winAlcon acquires Neurotech: The Swiss eye specialist paid $550 million upfront to acquire Neurotech Pharmaceuticals and could make additional payments if certain milestones are met. Alcon gains hold…endpoints · 28d ago
- Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug dataBausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.biopharma_dive · 1mo ago
- AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPDWith a detailed data drop that AstraZeneca’s R&D chief describes as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become…fiercebiotech · 2mo ago
- AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis winEven without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for Dupixent in eosinophilic esophagitis.biospace · 2mo ago
- New data could widen use of AstraZeneca, Amgen immune disease drugTezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.biopharma_dive · 2mo ago
- AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitisAstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion i…biospace · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that